Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.32 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.32 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.32 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.32 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | TYR | P14679 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL406816 | 0.98 | ALOX15 (0.34) | LMNATP53CYP3A4HPGDALOX15 | |
| SCHEMBL29373209 | 0.98 | ALOX15 (0.34) | LMNATP53CYP3A4HPGDALOX15 | |
| SCHEMBL9007666 | 0.87 | LMNA (0.31) | LMNATP53CYP3A4HPGDALOX15 | |
| SCHEMBL26698111 | 0.85 | LMNA (0.30) | LMNATP53CYP3A4HPGDALOX15 | |
| SCHEMBL15133340 | 0.85 | KDM4E (0.38) | HPGDALOX15CYP2C19ALDH1A1CA2 | |
| SCHEMBL30816714 | 0.85 | KDM4E (0.38) | HPGDALOX15CYP2C19ALDH1A1CA2 | |
| SCHEMBL14423397 | 0.84 | LMNA (0.33) | LMNATP53CYP3A4HPGDALOX15 | |
| SCHEMBL7949644 | 0.82 | LMNA (0.32) | LMNATP53CYP3A4HPGDALOX15 | |
| SCHEMBL31572308 | 0.82 | ALOX15 (0.36) | LMNATP53CYP3A4HPGDALOX15 | |
| SCHEMBL29871222 | 0.82 | ALOX15 (0.36) | LMNATP53CYP3A4HPGDALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250340578-A1 | NEW SUBSTITUTED PHOSPHITE TRANSITION METAL COMPOUNDS | MOMENTIVE PERFORMANCE MAT GMBH (DE) | 2025-11-06 | — | — | US | disclosed |
| EP-4532506-A1 | NEW SUBSTITUTED PHOSPHITE TRANSITION METAL COMPOUNDS | Momentive Performance Materials GmbH (DE) | 2025-04-09 | — | — | EP | disclosed |
| WO-2023227714-A1 | NEW SUBSTITUTED PHOSPHITE TRANSITION METAL COMPOUNDS | MOMENTIVE PERFORMANCE MATERIALS GMBH (DE) | 2023-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250340578-A1 | NEW SUBSTITUTED PHOSPHITE TRANSITION METAL COMPOUNDS | POF1B, PHOSPHO1, SLC40A1 | LMNA 2438/4885TP53 1460/4885CYP3A4 1711/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.